Stock Financial Ratios, Dividends, Split History

JNS / Janus Capital Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,611.27
Book Value ($M)1,652.10
Book Value / Share8.97
Price / Book1.58
NCAV ($M)-296.10
NCAV / Share-1.61
Price / NCAV-8.82
Share Statistics
Common Shares Outstanding 184,300,141
Common Stock Shares Outstanding 182,671,008
Weighted Average Number Of Diluted Shares Outstanding 181,200,000
Weighted Average Number Of Shares Outstanding Basic 177,000,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.07
Return on Assets (ROA)0.05
Return on Equity (ROE)0.10
Balance Sheet (mrq) ($M)
Quick Ratio3.25
Current Ratio3.25
Income Statement (mra) ($M)
Shareowner Servicing Fees And Other Revenue169,100,000.00
Operating Income261.60
Net Income151.30
Earnings Per Share Diluted0.78
Earnings Per Share Basic0.79
Cash Flow Statement (mra) ($M)
Cash From Operations262.20
Cash from Investing13.30
Cash from Financing262.20
Identifiers and Descriptors
Central Index Key (CIK)1065865
Related CUSIPS
047102X10 47102X905 47102X955

Split History

Stock splits are used by Janus Capital Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Bill Gross’s Janus Unconstrained Bond Fund Drops Sharply - WSJ

2018-05-30 wsj
Bill Gross’s Janus Henderson Global Unconstrained Bond Fund dropped more than 3% on Tuesday, an unusually big decline for a mutual fund that invests in corporate bonds and other fixed-income securities. (2-0)

Billion-Dollar Unicorns: What's Okta's Inorganic Growth Narrative?

2018-04-20 seekingalpha
Okta realizes the importance of partnering with other players like SailPoint and Palo Alto Networks to keep the bigger players at bay. (138-0)

Janus Henderson chief insists dual-class listings in Hong Kong must have solid corporate governance standards

2018-04-01 scmp
Hong Kong’s new listing reforms, due to kick-start later this month, are likely to attract more technology firms to list on its stock exchange – but only as long as the authorities can provide appropriate investor protection measures, the head of leading global fund manager Janus Henderson Investors has cautioned. (2-0)

CUSIP: 47102X105